TALi appoints former Cochlear executive as Chief Medical Officer
ASX-listed TALi Digital has appointed Mary Elizabeth Brinson, former vice president, Global Clinical Affairs, Cochlear, as its new Chief Medical Officer.
Mary Beth has held a number of senior clinical roles during a 16-year career at Cochlear including Director of Quality, Clinical and Regulatory Services and Director of Clinical Services, Research and Professional Training. She is a qualified audiologist and has practised in health care and academia in the US and United Kingdom. She is also an Adjunct Fellow at Macquarie University in Sydney.
Mary Beth holds a Doctorate in Audiology from the University of Louisville in Kentucky, a Master of Business Administration from Rutgers University in New Jersey and a Bachelor’s degree in Audiology and Speech Pathology from the University of Georgia in the United States.
“We’re thrilled to be able to welcome Mary Beth to the management team,” said TAli Chair Sue MacLeman. “She is joining at a pivotal time as we work toward a submission to the U.S. Food and Drug Administration ahead of a launch in that market next year.
“Mary Beth’s background in hearing, itself a cognitive function, provides an excellent foundation for supporting TALi mission to bring the benefits of strong attention to young children. Her experience leading global clinical affairs at Cochlear, one of the world’s most successful medical devices businesses, will be invaluable as we work to make the benefits of TALi’s innovative digital therapeutic available in other markets.”
Dr Brinson will have overall responsibility for all clinical, regulatory and quality activities at TALi, including the clinical development phase of the company’s U.S. Strategic License Agreement with Akili and hold the title Chief Medical Officer.
The inability to stand on one leg for 10 seconds in mid to later life is linked to an increased...
Their detailed report provides a blueprint for governments, academics, health professionals and...
A postpartum depression drug that currently must be administered as a 60-hour intravenous...